
    
      This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group
      study, to assess the efficacy and safety of SPN-812 ER as monotherapy for the treatment of
      adolescents 12-17 years old with ADHD.
    
  